Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Articles|December 23, 2020
- MHE December 2020
- Volume 30
- Issue 12
MHE State of the Industry survey: The COVID-19 vaccine
Author(s)MHE Staff
In this second of a six-part series, the biggest concern is short supply.
Advertisement
The State of the Industry survey was conducted in October and November before the FDA granted emergency use authorizations for the Pfizer-BioNTech and the Moderna vaccines. Roughly one-third (32%) of the respondents indicated that they were extremely concerned about the vaccine being in short supply, and 41% were indicated that level of concern about a large percentage of American not getting vaccinated.
Articles in this issue
almost 6 years ago
MHE State of the Industry survey: Healthcare disparities and racismalmost 6 years ago
MHE State of the Industry survey: The shift to value-based carealmost 6 years ago
MHE State of the Industry survey: The pandemic’s effectsalmost 6 years ago
MHE State of the Industry survey: COVID-19 ranks No.1almost 6 years ago
The Pandemic Opens a Window of Opportunity for Telehealthalmost 6 years ago
MA stargazing reveals a different storyalmost 6 years ago
Medicare Advantage Enrollment Keeps Growingalmost 6 years ago
2020 drug approvals: not bad, consideringAdvertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
3
Jessica Castle, M.D., discusses CGM’s A1C impact in non-insulin type 2 diabetes
4
Eric K. Singhi, M.D., on lung cancer among younger adults
5